- Home
- WGS vs BXMX Comparison
WGS vs BXMX Comparison
Compare WGS & BXMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGS
- BXMX
- Stock Information
- Founded
- WGS 2017
- BXMX 2004
- Country
- WGS United States
- BXMX United States
- Employees
- WGS N/A
- BXMX N/A
- Industry
- WGS Retail: Computer Software & Peripheral Equipment
- BXMX Investment Managers
- Sector
- WGS Technology
- BXMX Finance
- Exchange
- WGS Nasdaq
- BXMX Nasdaq
- Market Cap
- WGS 1.5B
- BXMX 1.5B
- IPO Year
- WGS N/A
- BXMX N/A
- Fundamental
- Price
- WGS $68.43
- BXMX $13.78
- Analyst Decision
- WGS Strong Buy
- BXMX
- Analyst Count
- WGS 5
- BXMX 0
- Target Price
- WGS $67.00
- BXMX N/A
- AVG Volume (30 Days)
- WGS 753.8K
- BXMX 205.6K
- Earning Date
- WGS 10-29-2024
- BXMX 01-01-0001
- Dividend Yield
- WGS N/A
- BXMX 7.24%
- EPS Growth
- WGS N/A
- BXMX N/A
- EPS
- WGS N/A
- BXMX N/A
- Revenue
- WGS $267,228,000.00
- BXMX N/A
- Revenue This Year
- WGS $43.70
- BXMX N/A
- Revenue Next Year
- WGS $16.78
- BXMX N/A
- P/E Ratio
- WGS N/A
- BXMX N/A
- Revenue Growth
- WGS 29.41
- BXMX N/A
- 52 Week Low
- WGS $1.29
- BXMX $11.75
- 52 Week High
- WGS $89.11
- BXMX $13.75
- Technical
- Relative Strength Index (RSI)
- WGS 51.05
- BXMX 51.75
- Support Level
- WGS $71.45
- BXMX $13.53
- Resistance Level
- WGS $82.18
- BXMX $13.98
- Average True Range (ATR)
- WGS 7.58
- BXMX 0.11
- MACD
- WGS -1.36
- BXMX 0.00
- Stochastic Oscillator
- WGS 17.21
- BXMX 54.35
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.